UWS BREATH/IBEHR PhD Team Visit GlaxoSmithKline

Principal investigators and PhD students from UWS, DkIT and QUB at the Brentford GSK site.

GlaxoSmithKline (GSK) is currently one of the largest health care and pharmaceutical companies with an annual turnover of £30.8bn per annum. This month eight UWS PhD students from the Border & Regions Airways Training Hub (BREATH) and the Institute of Biomedical & Environmental Health Research (IBEHR) were invited to the Brentford and Stevenage GSK sites for a two day visit. They formed part of a larger BREATH team of thirty-five scientists from the Dundalk Institute of Technology (DkIT) and Queen’s University Belfast (QUB).

The collective team were given guided tours of the facilities and presentations by GSK scientists, engineers, marketing executives, department heads and researchers, all of whom are vital to the process of product development from research and innovation to distribution. Students and principal investigators had the unique opportunity to engage with associates of the company and learn about their recent work. This included the utilisation of deep learning to improve diagnostics, the use of virtual reality to train the workforce in key techniques, the process of guiding a product from pre-market to market and the general process by which teams of multidisciplinary scientists design, manufacture and test products.

All visiting PhDs appreciated the chance to visit GSK and wish to thank GSK Medical Scientific Liaison, Alan Ullman, GSK Director of Scientific Engagement, Gordon Hutchinson, and QUB Professor Lorcan McGarvey (UWS Visiting Professor) for organising the visit. It proved an excellent opportunity for the group to network and become informed of the different requirements and routes available, especially for those considering industry as a career direction after the completion of their doctoral studies. GSK is major constituent of the global pharmaceutical industry as is reflected by the company’s £3.9bn investment in research and development over the last year and their collaborations with research teams throughout the world. Additionally, GSK commits to all clinical trial data being published within 18 months of operation cessation.

Please note the links below for anyone wishing to follow the progress of the BREATH and CMS teams:

Facebook: Centre for Musculoskeletal Science

Twitter: @Breath_COPD & @cms_uws

UWS PhD Students: Carly Woods, Mari Bailo, Fawziye Tarhini, Sabha Asghar, Bryn Short, Kirsty McCallum, Mark Thomas, Kimberly Black.